What You Should Know:
– Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), has announced the merger with COTA Healthcare®.
– The merger expands the company’s therapeutic offerings in data and software solutions for real-world insights that accelerate clinical research, expedite treatment options, and improve patient care. Terms of the transaction were not disclosed.
Building a Multi-Specialty Engine for Research-Grade Real-World Data
Verana Health is redefining how real-world data (RWD) is translated into clinical insight and regulatory-grade evidence. By combining deep physician expertise with artificial intelligence, the company unlocks the full potential of large-scale, specialty-specific patient data—turning routine clinical encounters into powerful real-world evidence (RWE).
With exclusive access to some of the world’s largest patient data sources across ophthalmology, urology, neurology, and oncology, Verana Health supports clinicians seeking to improve care quality and outcomes, while enabling life sciences companies to accelerate the development, evaluation, and approval of new therapies.
The integration of COTA Healthcare significantly strengthens this mission. Together, the companies will deliver more clinically rich, deeply curated, and research-ready datasets designed to meet the evidentiary standards required for high-stakes clinical, commercial, and regulatory decision-making.
Why the Combination Matters for Life Sciences and Regulators
COTA Healthcare’s strength in high-fidelity oncology data meaningfully complements Verana Health’s established leadership across other specialties. The combined portfolio now supports a broad range of use cases across the product lifecycle, including:
• Clinical trial design, feasibility, and external control arms
• Regulatory submissions and post-market evidence generation
• Health economics and outcomes research (HEOR)
• Market-access and reimbursement strategy
• MIPS advisory and quality reporting for clinicians
By expanding into oncology with COTA’s advanced curation and analytics capabilities, Verana Health raises the bar for data quality, validation, and transparency—key attributes for organizations working closely with the U.S. Food and Drug Administration and other global regulators.
As Verana Health CEO Sujay Jadhav noted, the combination broadens the company’s ability to serve life sciences partners with confidence, ensuring that insights derived from real-world data are both clinically grounded and methodologically rigorous.
Verana Health’s leadership in RWE is anchored in its exclusive partnerships with some of the most trusted physician-led clinical registries in medicine, including:
• The American Academy of Ophthalmology IRIS Registry
• The American Urological Association AQUA Registry
These disease-specific datasets are curated with direct physician involvement, ensuring clinical relevance while maintaining the scale required for advanced analytics and AI-driven discovery. The addition of COTA’s oncology datasets extends this registry-driven approach into cancer care, delivering deeper longitudinal insight into treatment patterns, outcomes, and real-world effectiveness.
Together, Verana Health and COTA Healthcare represent a new class of RWD platform—one that combines specialty depth, regulatory expertise, and advanced analytics into a single, scalable infrastructure for evidence generation.
For life sciences organizations navigating increasingly complex regulatory expectations and value-based care environments, the joint entity offers something rare: real-world data that is not only large and timely, but clinically interpretable, transparent, and trusted.
By uniting physician-led data, AI-driven curation, and multi-specialty reach, Verana Health is positioning itself as a top-tier partner for accelerating clinical research, regulatory success, and ultimately, better patient outcomes across medicine.
